Kesimpta (Ofatumumab) is indicated for the treatment of:
c. Multiple sclerosis
d. Type II diabetes
The active ingredient found in Kesimpta is Ofatumumab. It is available in a single-dose prefilled syringe.
Kesimpta (Ofatumumab) is a CD20-directed cytolytic antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
The precise mechanism by which Ofatumumab exerts its therapeutic effects in multiple sclerosis is unknown, but is presumed to involve binding to CD20, a cell surface antigen present on pre-B and mature B lymphocytes. Following cell surface binding to B lymphocytes, ofatumumab results in antibody-dependent cellular cytolysis and complement-mediated lysis.
Hepatitis B virus (HBV) and quantitative serum immunoglobulins screening are required before the first dose.
Initial Dosing: 20 mg subcutaneously administered at Week 0, 1, and 2.
Subsequent Dosing: 20 mg subcutaneously administered monthly starting at Week 4.
Respiratory tract infection, headache, injection-related reactions, and local injection site reactions are reported side effects of drug.
Try our Naplex QBank. www.pharmacyexam.com **Please note: This type of question will not show up in an MPJE. We are just posting to MPJE group for knowledge.